The Targeted Pulse: A Milestone Week for Oncology Innovation

Welcome to this week's edition of The Targeted Pulse. This week in oncology, we saw a number of significant developments, from FDA approvals to promising clinical trial data for various cancer types. Here is a summary of the top stories.

Oncology Frontiers: Recapping a Milestone February for FDA Approvals

In February 2026, the FDA reached a significant milestone by granting several key oncology approvals and designations across diverse cancer types. Highlights include a new tumor treating fields (TTFields) therapy, Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel, and amivantamab-vmjw and hyaluronidase-lpuj (Rybrevant Faspro) for a subcutaneous (SC) dosing regimen that allows for once-monthly administration following an initial induction phase for patients with with locally advanced or metastatic non–small cell lung cancer

The agency also expanded its focus on precision medicine, granting designations for an AI-based prognostic tool for lung cancer and an AI-driven detection software for prostate cancer. These regulatory actions signify a robust shift toward personalized therapies, addressing critical unmet needs in both rare and common malignancies.

Navigating Resistance and Intolerance in High-Risk Polycythemia Vera

Experts explore management strategies for patients who fail first-line hydroxyurea (HU) therapy. Approximately 25-30% of patients develop resistance or intolerance, marked by persistent erythrocytosis, symptomatic splenomegaly, or severe toxicities like leg ulcers.

Clinicians emphasize transitioning to second-line options, such as ruxolitinib (Jakafi) or ropeginterferon alfa-2b. Ruxolitinib is highlighted for its efficacy in controlling hematocrit and reducing spleen size, while ropeginterferon offers sustained molecular responses and long-term event-free survival. The experts stress that timely recognition of HU failure is critical to reducing thrombotic risks and improving quality of life through personalized, second-line interventions.

Final KEYNOTE-B96 Analysis Confirms Survival Benefits With Pembrolizumab Regimen in Ovarian Cancer

The final analysis of the phase 3 KEYNOTE-B96 trial demonstrates that adding pembrolizumab (Keytruda) to paclitaxel, with or without bevacizumab (Avastin), significantly improves survival in platinum-resistant recurrent ovarian cancer. For the first time, a PD-1 inhibitor-based regimen has shown a statistically significant overall survival benefit in this population, reducing the risk of death by 18% in all-comers and 24% in those with PD-L1 expression (CPS ≥1).

Following these results, the FDA approved the combination in February 2026 for PD-L1-positive patients. While the regimen increased certain treatment-related adverse events like colitis, it offers a vital new option for a difficult-to-treat malignancy.

FDA Issues Tentative Approval to Lu 177 Dotatate Radioequivalent for GEP-NETs

The FDA has granted tentative approval to PNT2003, the first "radioequivalent" version of lutetium Lu 177 dotatate (Lutathera), for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. This regulatory milestone indicates that the drug meets all safety, quality, and efficacy standards for domestic marketing.

Developed by Lantheus, PNT2003 is a radiopharmaceutical that delivers targeted radiation to cancer cells. While the FDA has completed its review, final approval is currently pending the expiration of existing patent exclusivity for the reference drug, expected in June 2026. This approval aims to expand patient access to critical peptide receptor radionuclide therapy.

Belzutifan/Palbociclib Fails to Yield High ORR in Pretreated ccRCC

Findings from part 1 of the phase 1/2 LITESPARK-024 trial, evaluating the combination of the HIF-2α inhibitor belzutifan (Welireg) and the CDK4/6 inhibitor palbociclib (Ibrance) in heavily pretreated patients with advanced clear cell renal cell carcinoma, demonstrated a manageable safety profile.

Results showed a manageable safety profile with no new toxicities, though grade 3 anemia and neutropenia were common. However, the objective response rate was only 12.1% overall and 21.1% at the recommended dose—comparable to historical belzutifan monotherapy. Consequently, the combination will not move into part 2 of the trial.